+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Tyrosine Kinase Inhibitors Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896100
  • Report
  • January 2020
  • Region: Global
  • 115 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Eisai
  • F. Hoffmann-La Roche
  • Johnson and Johnson
  • MORE
Market Overview

A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell. A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases.

Recently, due to the increasing prevalence of cancer incidence globally, the demand for novel therapies for treatment has increased. Theoretically, TKI, which is a small molecule, has many advantages over traditional therapies including ease of oral administration, and the ability to target multiple cellular survival pathways. As a result, many researches are being done in order to find cancer treatment theories that involve TKI. Many drugs involving this pathway are under development. These factors are expected to help the growth of the market.

However, high development cost leads to the higher market price of the drug post-approval. Hence the cost of the drug has been restraining the market growth up to a certain extent.

Scope of the Report

A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades.

In the report, a detailed analysis of the tyrosine kinase inhibitor market is provided. The market is evaluated by collating revenues generated across segments, categorized by type, application and geography.

Key Market Trends

Treatment for Chronic Myeloid Leukaemia is Expected to Dominate the Market

Chronic Myeloid Leukemia (CML) is a cancer of the white blood cells which is characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. The incidence of CML has increased over the course of the past few decades as per research by Taisen Hao et al., published in Nature Research Journal 2019. As per the reports CML cases increased from 4,300 cases in 1998 to 8,430 in 2018, up by 96%, in the United States.

CML is largely treated with targeted drugs called tyrosine-kinase inhibitors (TKIs) which have led to dramatically improved long-term survival rates since the early 2000s. These drugs have said to have revolutionized the treatment of this disease by allowing most patients to have a good quality of life when compared to the former chemotherapy drugs.

Hence, with the growing incidence of CML, the market for tyrosine kinase inhibitors therapies is also expected to increase.

North America is Expected to Dominate the Market

The North American countries including the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development, especially on Cancer. Many companies in these countries have been involved in cancer research. These policies have, hence, encouraged other global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players.

Moreover, the prevalence of cancer is also high in these countries. The prevalence of cancer in the United States (US) is one of the highest in the world. As per a 2018 report by the World Cancer Research Fund International, the prevalence of cancer in the US is 352.2 per 100,000. As per the same report, Canada also has a high prevalence of cancer with 334 per 100,000 Canadians suffering from the dreadful disease. This high prevalence of cancer has increased the economic burden of cancer of the population of this region.

Hence, as high demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

The majority of the tyrosine kinase inhibitors therapies are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market grow at a significant rate.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Eisai
  • F. Hoffmann-La Roche
  • Johnson and Johnson
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer
4.2.2 Growing Research Activities and Investment in Tyrosine Kinase Inhibitors
4.3 Market Restraints
4.3.1 High Cost of Therapy
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 BCR-ABL Tyrosine Kinase Inhibitor
5.1.2 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
5.1.3 Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
5.1.4 Others
5.2 By Application
5.2.1 Chronic Myeloid Leukemia (CML)
5.2.2 Lung Cancer
5.2.3 Breast Cancer
5.2.4 Renal Cell Cancer
5.2.5 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Bayer
6.1.3 Boehringer Ingelheim International
6.1.4 Bristol-Myers Squibb
6.1.5 Eisai
6.1.6 F. Hoffmann-La Roche
6.1.7 Johnson and Johnson
6.1.8 Novartis
6.1.9 Pfizer

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim International
  • Bristol-Myers Squibb
  • Eisai
  • F. Hoffmann-La Roche
  • Johnson and Johnson
  • Novartis
  • Pfizer
Note: Product cover images may vary from those shown